Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29756469 | 1.00 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTGAAMAPK1 | |
| Hydrochloric Acid SCHEMBL2259015 | 0.98 | ALDH1A1 (0.42) | ALDH1A1KDM4EMAPTGAAMAPK1 | |
| SCHEMBL9251303 | 0.83 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTGAAMAPK1 | |
| SCHEMBL6705874 | 0.83 | MTNR1A (0.49) | ALDH1A1KDM4EMAPTGAAMAPK1 | |
| SCHEMBL13362022 | 0.82 | GAA (0.46) | MAPTGAAARPNMT | |
| SCHEMBL5807102 | 0.79 | GAA (0.46) | MAPTGAAARPNMT | |
| SCHEMBL11491245 | 0.79 | MTNR1A (0.37) | MAPTGAAPRCPARPNMT | |
| SCHEMBL11771368 | 0.78 | ALDH1A1 (0.40) | ALDH1A1KDM4EMAPTGAAMAPK1 | |
| SCHEMBL11426860 | 0.77 | GAA (0.47) | MAPTGAAARPNMT | |
| SCHEMBL7131825 | 0.77 | ALDH1A1 (0.37) | ALDH1A1KDM4EMAPTGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9143158-A | — | — | None | — | — | JP | disclosed |
| EP-2225223-B1 | ORGANIC COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2017-01-11 | — | — | EP | disclosed |
| EP-2251338-A2 | Organic compounds | Boehringer Ingelheim International GmbH (DE) | 2010-11-17 | — | — | EP | disclosed |
| US-6825225-B2 | useful against a number of human and veterinary pathogens, including gram-positive aerobic bacteria such as multiply-resistant staphylococci and streptococci, anaerobic organisms such as bacteroides and clostridia species, and acid-fast organisms | PHARMACIA & UPJOHN COMPANY | 2004-11-30 | — | — | US | disclosed |
| US-20040116413-A1 | Novel bicyclic isoxazolinones as antibacterial agents | PHARMACIA & UPJOHN COMPANY | 2004-06-17 | — | — | US | disclosed |
| EP-0831829-B1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER (US) | 2003-08-20 | — | — | EP | disclosed |
| EP-1334090-A1 | NOVEL BICYCLIC ISOXAZOLINONES AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-1181288-B1 | BICYCLIC OXAZOLIDINONES AS ANTIBACTERIAL AGENT | UPJOHN CO (US) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002102785-A1 | NOVEL BICYCLIC ISOXAZOLINONES AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-27 | — | — | WO | disclosed |
| US-20020143009-A1 | Novel bicyclic oxazolidinones as antibacterial agents | PHARMACIA & UPJOHN | 2002-10-03 | — | — | US | disclosed |
| EP-1181288-A1 | BICYCLIC OXAZOLIDINONES AS ANTIBACTERIAL AGENT | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000073301-A1 | BICYCLIC OXAZOLIDINONES AS ANTIBACTERIAL AGENT | PHARMACIA & UPJOHN COMPANY (US) | 2000-12-07 | — | — | WO | disclosed |
| EP-0831829-A4 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER (US) | 1998-11-25 | — | — | EP | disclosed |
| US-5736534-A | HYPERPROLIFERATIVE DISEASES; INHIBITORS OF PROTEIN-TYROSINE KINASES SUCH AS EPIDERMAL GROWTH FACTOR RECEPTOR; BRAIN, LUNG, BREAST CANCER; PSORIASIS AND BENIGN PROSTATE HYPERPLASIA | PFIZER INC. (US) | 1998-04-07 | — | — | US | disclosed |
| EP-0831829-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| JP-H09143158-A | PRODUCTION OF 2-ALKYLINDOLINE | KAWAKEN FINE CHEM CO LTD | 1997-06-03 | — | — | JP | disclosed |
| CN-1141298-A | Pyrimidine-fused heterocyclic compound anti-cancer agents | PFIZER (US) | 1997-01-29 | — | — | CN | disclosed |
| WO-1996040142-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0746554-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995023141-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1995-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143009-A1 | Novel bicyclic oxazolidinones as antibacterial agents | OXA1L, MRPL21, RPS4Y1 | ALDH1A1 1430/4885KDM4E 3964/4885MAPT 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.